Komatsu Aoi, Higashi Yuya, Lin Cong-Kai, Chen Yi-Ping, Wu Si-Han, Suzuki Minoru, Matsumoto Kotaro, Tamanoi Fuyuhiko
Institute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University, Kyoto 606-8501, Japan.
Graduate Institute of Nanomedicine and Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Cells. 2025 May 17;14(10):734. doi: 10.3390/cells14100734.
(1) Background: The chorioallantoic membrane (CAM) model has the potential to contribute to the development of personalized medicine based on individual cancer patients. We previously established the CAM model using patient-derived sarcoma cells. We also used the CAM model for characterization and a comparison with the mouse model by examining the tumor accumulation of small-size, highly dispersive mesoporous silica nanoparticles (MSNs). (2) Method: In this study, we transplanted a variety of cancer cell lines, including patient-derived osteosarcoma (OS) and extraskeletal osteosarcoma (ESOS) cells. Patient-derived OS, ESOS and other cell lines were transplanted onto CAMs. The proliferation of cancer cells within CAM tumors was confirmed using H&E staining. For the comparison of the CAM and mouse models, rhodamine B-labeled MSNs were administered intravenously to CAMs and to xenograft mice. Tumor accumulation was evaluated by examining fluorescence and by confocal microscopy. The biodistribution of MSNs was examined by measuring the Si content by ICP. (3) Results: H&E staining demonstrated the proliferation of cancer cells of OS, ESOS and others on CAMs. While growth patterns and morphologies varied among different cancer types, H&E staining confirmed the establishment of tumors. As for the tumor accumulation, both the CAM and mouse models showed that MSNs were selectively accumulated in the tumors in both the CAM and mouse models. (4) Conclusions: We have expanded the range of CAM models by using a variety of cancer cells, including patient-derived cell lines. We also report that the small-size, highly dispersive MSNs exhibit excellent tumor accumulation in both the CAM and mouse models. These results point to the usefulness of the CAM model for patient-derived cancer cells as well as for evaluating drug carriers for tumor targeting.
(1) 背景:绒毛尿囊膜(CAM)模型有潜力推动基于个体癌症患者的个性化医疗发展。我们之前使用患者来源的肉瘤细胞建立了CAM模型。我们还通过检测小尺寸、高分散性介孔二氧化硅纳米颗粒(MSN)在肿瘤中的蓄积情况,利用CAM模型进行表征并与小鼠模型作比较。(2) 方法:在本研究中,我们移植了多种癌细胞系,包括患者来源的骨肉瘤(OS)和骨外骨肉瘤(ESOS)细胞。将患者来源的OS、ESOS及其他细胞系移植到CAM上。使用苏木精-伊红(H&E)染色确认CAM肿瘤内癌细胞的增殖。为比较CAM和小鼠模型,将罗丹明B标记的MSN静脉注射到CAM和异种移植小鼠体内。通过检测荧光和共聚焦显微镜评估肿瘤蓄积情况。通过电感耦合等离子体质谱(ICP)测量硅含量来检测MSN的生物分布。(3) 结果:H&E染色显示OS、ESOS和其他癌细胞在CAM上增殖。虽然不同癌症类型的生长模式和形态各不相同,但H&E染色证实了肿瘤的形成。至于肿瘤蓄积,CAM和小鼠模型均显示MSN在CAM和小鼠模型的肿瘤中均有选择性蓄积。(4) 结论:我们通过使用多种癌细胞,包括患者来源的细胞系,扩大了CAM模型的范围。我们还报告称,小尺寸、高分散性的MSN在CAM和小鼠模型中均表现出优异的肿瘤蓄积能力。这些结果表明CAM模型对于患者来源的癌细胞以及评估用于肿瘤靶向的药物载体是有用的。